Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.6
2.6
Journals
Medicina
Special Issues
Chronic Inflammatory Skin Disease: Where We Are and Where We...
share announcement

Chronic Inflammatory Skin Disease: Where We Are and Where We Are Going

A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Dermatology".

Deadline for manuscript submissions: 30 June 2024 | Viewed by 9788

Special Issue Editors

Dr. Fabrizio Martora

E-Mail Website
Guest Editor
Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, 80131 Naples, Italy
Interests: hidradenitis suppurativa; psoriasis; atopic dermatitis; new treatment; skin inflammatory disease
Special Issues, Collections and Topics in MDPI journals
Dr. Matteo Megna

E-Mail Website
Guest Editor
Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, 80131 Napoly, Italy
Interests: inflammatory skin diseases; psoriasis; hidradenitis; atopic dermatitis; acne and rosacea; infective diseases; ontological diseases in dermatology (including melanoma and nonmelanoma skin cancers); teledermatology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Significant progress has been achieved in the last few decades in dermatology, especially regarding chronic inflammatory skin diseases. In recent years, great progress has also been made in understanding the pathogenesis of the most common inflammatory skin diseases such as psoriasis, atopic dermatitis, and hidradenitis suppurativa that has led to the development of selective and targeted innovative therapies. In particular, biological drugs (chimeric, humanized, and fully human monoclonal antibodies), biosimilars, and small molecules have completely revolutionized the treatment of chronic inflammatory skin diseases by opening new avenues for us clinicians. However, significant research efforts are still needed. New studies are needed to identify biomarkers for each disease, so that we clinicians may be able to diagnose and treat chronic inflammatory diseases early and predict responses to treatments so that we can choose the best treatment for each type of patient.

This Special Issue entitled “Chronic Inflammatory Skin Disease: Where We Are and Where We Are Going” is now open for submissions, welcoming papers that aim to bring together the most relevant scientific research on chronic inflammatory skin diseases, focusing on epidemiology, pathophysiology, and recent or emerging advances in therapy.

Dr. Fabrizio Martora
Dr. Matteo Megna
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

 

Keywords

  • psoriasis
  • atopic dermatitis
  • hidradenitis suppurativa
  • skin inflammatory disease

Published Papers (6 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

11 pages, 629 KiB  
Article
Skin-Related Sexual Life Questionnaire (SRSLQ): Creation and Validation of the Questionnaire
by Kamila Kędra and Adam Reich
Medicina 2023, 59(11), 2023; https://doi.org/10.3390/medicina59112023 - 17 Nov 2023
Viewed by 988
Abstract
Background and Objectives: The assessment of sexual dysfunction among psoriatic patients still remains a great diagnostic difficulty due to its subjective and embarrassing character. Various questionnaires have been used to assess sexual dysfunctions associated with skin conditions; however, none of them have [...] Read more.
Background and Objectives: The assessment of sexual dysfunction among psoriatic patients still remains a great diagnostic difficulty due to its subjective and embarrassing character. Various questionnaires have been used to assess sexual dysfunctions associated with skin conditions; however, none of them have been approved as a gold standard. The aim of our study was to create and validate the Skin-Related Sexual Life Questionnaire (SRSLQ) for the assessment of possible sexual dysfunction and related psychological burdens in patients with skin diseases. Materials and Methods: A total of 109 patients, including 45 women and 64 men (1:1.4) suffering from psoriasis and aged between 18 and 73 years (mean 48.0 ± 13.4 years), were included in the study. All subjects completed the 11-item SRSLQ and the Dermatology Life Quality Index (DLQI). In addition, all men were asked to fulfil the five-item version of the International Index of Erectile Dysfunction (IIEF-5) at the time of examination and 7 days after enrollment. The disease severity was assessed via the PASI scale. Results: The statistical analysis of internal consistency of SRSLQ showed very good integrity, with a Cronbach α coefficient of 0.94. The reproducibility level assessed with intraclass correlation coefficient (ICC) amounted to 0.96. A significant correlation between the total score of the 11-item SRSDQ and the DLQI (r = 0.39; p < 0.001) was found, confirming congruent validity. Conclusions: The validated 11-item Skin-Related Sexual Life Questionnaire can be successfully implemented in daily clinical practice as well as in clinical research. Full article
(This article belongs to the Special Issue Chronic Inflammatory Skin Disease: Where We Are and Where We Are Going)
►▼ Show Figures

Figure 1

11 pages, 1883 KiB  
Article
Cutaneous Toll-like Receptor 9 Pre-Defines Hydroxychloroquine Dosage in Patients with Both Discoid and Subacute Lupus Erythematosus
by Karolina A. Englert, Grzegorz Dyduch, Agata Kłosowicz, Magdalena Spałkowska, Andrzej Kazimierz Jaworek, Kamila Migacz-Gruszka, Aleksandra Jarosz-Chudek, Santo Raffaele Mercuri, Joanna Szpor, Gianluigi Mazzoccoli, Giovanni Damiani and Anna Wojas-Pelc
Medicina 2023, 59(11), 2022; https://doi.org/10.3390/medicina59112022 - 17 Nov 2023
Viewed by 881
Abstract
Background and Objectives: Cutaneous lupus erythematosus (CLE) presents clinically heterogeneous manifestations, partially explained by the different expression of Toll-like receptors (TLRs) type 8 and 9, located to endosomal compartments where they are poised to recognize microbial nucleic acids. This disease is empirically [...] Read more.
Background and Objectives: Cutaneous lupus erythematosus (CLE) presents clinically heterogeneous manifestations, partially explained by the different expression of Toll-like receptors (TLRs) type 8 and 9, located to endosomal compartments where they are poised to recognize microbial nucleic acids. This disease is empirically treated with hydroxychloroquine (HCQ), which is hallmarked with a safe and effective profile, but induces a slow and sometimes clinically insufficient therapeutic response. Currently, no biomarkers predictive of response are validated or even proposed in the scientific literature. We aimed to evaluate endosomal TLR type 7, 8 and 9 as predictive biomarkers of HCQ efficacy. Materials and Methods: We conducted a case–control study comparing CLE patients retrospectively assigned to three subgroups based on 3–6-month Cutaneous LE Disease Area and Severity Index (CLASI) reduction upon treatment with HCQ (I = <40% vs. II = 40–80% vs. III = >80%). Before HCQ, lesional skin specimens were collected in untreated CLE and through immunohistochemistry; TLR-7, -8 and -9 expression was evaluated in the epidermis and the lymphocytic infiltrate was evaluated in the dermis. Results: Sixty-six lesional skin biopsies were compared with healthy controls. CLE patients displayed lower epidermal expression of total TLR 8 and 9 as well as infiltrating TLR-8, TLR9 + lymphocytes compared to controls. High HCQ responders differed from low responders for TLR-9 positivity (high vs. low) and for the lymphocytic dermal infiltrate (high vs. low). Conclusions: TLR9 could be envisaged as a possible biomarker to predict HCQ response level and dosage in CLE patients. Full article
(This article belongs to the Special Issue Chronic Inflammatory Skin Disease: Where We Are and Where We Are Going)
►▼ Show Figures

Figure 1

13 pages, 1917 KiB  
Article
An Observational Study of 147 Psoriasis Patients: Overweightness and Obesity as a Significant Clinical Factors Correlated with Psoriasis
by Anna Czarnecka, Monika Zabłotna, Dorota Purzycka-Bohdan, Roman J. Nowicki and Aneta Szczerkowska-Dobosz
Medicina 2023, 59(11), 2006; https://doi.org/10.3390/medicina59112006 - 15 Nov 2023
Viewed by 1090
Abstract
Background and Objectives: Psoriasis is a common, chronic, and immune-mediated inflammatory skin disease recognized to lead to a wide range of comorbid disorders, mainly obesity. The study aimed to evaluate the problem of overweightness and obesity among psoriasis patients in the context [...] Read more.
Background and Objectives: Psoriasis is a common, chronic, and immune-mediated inflammatory skin disease recognized to lead to a wide range of comorbid disorders, mainly obesity. The study aimed to evaluate the problem of overweightness and obesity among psoriasis patients in the context of their prevalence and influence on the disease course. Materials and Methods: The study group encompassed 147 adult patients with plaque psoriasis. Results: The prevalences of overweightness (39.46%) and obesity (37.41%) demonstrated in the study showed the strong predisposition of psoriatic patients for abnormal body mass. The vast majority (77%) of subjects with psoriatic arthritis were overweight or obese. The results of the correlation analysis revealed the significant impacts of overweightness and obesity, as defined by the BMI index, on modifying the severity of psoriasis (as assessed by the PASI with a correlation coefficient of R = 0.23, p = 0.016; and BSA values with a correlation coefficient of R = 0.21, p = 0.023), particularly in contrast to patients with a normal body mass. Conclusions: Overweightness and obesity constitute a major health burden among psoriatic patients, influencing the disease course and severity. Enhanced understanding of the phenomenon may directly translate into improving disease management and overall patient care. Full article
(This article belongs to the Special Issue Chronic Inflammatory Skin Disease: Where We Are and Where We Are Going)
►▼ Show Figures

Figure 1

11 pages, 2991 KiB  
Article
The Anti-Inflammatory and Skin Barrier Function Recovery Effects of Schisandra chinensis in Mice with Atopic Dermatitis
by Yoorae Son, Wonjin Yang, Sangjun Park, Jinkyu Yang, Soyeon Kim, Ji-Hyo Lyu and Hyungwoo Kim
Medicina 2023, 59(7), 1353; https://doi.org/10.3390/medicina59071353 - 24 Jul 2023
Cited by 2 | Viewed by 1614
Abstract
Background and Objectives: The fruit of Schisandra chinensis (Turcz.) Baill. is widely used medicinally to treat coughs, asthma, exhaustion, eczema, and pruritus in Northeast Asian countries, including Korea, China, and Japan. This study was designed to investigate the effects of S. chinensis [...] Read more.
Background and Objectives: The fruit of Schisandra chinensis (Turcz.) Baill. is widely used medicinally to treat coughs, asthma, exhaustion, eczema, and pruritus in Northeast Asian countries, including Korea, China, and Japan. This study was designed to investigate the effects of S. chinensis on dermatitis in mice with calcipotriol (MC-903)-induced atopic dermatitis (AD), and its effects on skin barrier dysfunction was also investigated. Materials and Methods: The inhibitory effects of an ethanolic extract of S. chinensis (EESC) on skin lesions, water content, water-holding capacity (WHC), histopathological abnormalities, and inflammatory cytokine and chemokine levels were evaluated in mice with AD induced by MC903. Results: Topical EESC ameliorated skin lesions, reduced skin water content, and increased MC903-induced WHC. EESC also prevented MC-903-induced histopathological abnormalities such as epidermal disruption, hyperkeratosis, spongiotic changes, and immune cell infiltration in inflamed tissue. Moreover, topical EESC reduced MC-903-induced levels of pro-inflammatory cytokines and chemokines, such as tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-4, IL-6, IL-8, monocyte chemotactic protein (MCP)-1, and thymic stromal lymphopoietin (TSLP). Furthermore, unlike dexamethasone, EESC did not reduce the spleen/body weight ratio. Conclusions: These results suggest that S. chinensis can be used as an alternative to external corticosteroids and that its anti-inflammatory and skin barrier dysfunction-restoring effects are related to the downregulation of pro-inflammatory cytokines and chemokines, such as TNF-α, IL-4, IL-6, IL-8, and TSLP. Full article
(This article belongs to the Special Issue Chronic Inflammatory Skin Disease: Where We Are and Where We Are Going)
►▼ Show Figures

Figure 1

Review

Jump to: Research

14 pages, 963 KiB  
Review
Psoriasis: What Is New in Markers of Disease Severity?
by Mircea Tampa, Madalina Irina Mitran, Cristina Iulia Mitran, Clara Matei and Simona Roxana Georgescu
Medicina 2024, 60(2), 337; https://doi.org/10.3390/medicina60020337 - 18 Feb 2024
Viewed by 900
Abstract
Introduction. Psoriasis is a chronic inflammatory skin disease and is the result of the interaction between numerous external and internal factors. Psoriasis presents a wide range of skin manifestations encompassing individual lesions varying from pinpoint to large plaques that can evolve into [...] Read more.
Introduction. Psoriasis is a chronic inflammatory skin disease and is the result of the interaction between numerous external and internal factors. Psoriasis presents a wide range of skin manifestations encompassing individual lesions varying from pinpoint to large plaques that can evolve into generalised forms. The lesions mirror the pathophysiological mechanisms involved in psoriasis pathogenesis, such as inflammation, dysregulation of immune response, uncontrolled proliferation of keratinocytes and angiogenesis. In this article, we present the latest advances achieved regarding markers that correlate with psoriasis severity. Material and method. We have performed a narrative review on markers of psoriasis severity, including articles published between March 2018–March 2023. Results. We have identified four categories of markers: inflammation markers, oxidative stress markers, hormonal markers and cancer-related markers. The main focus was on inflammation biomarkers, including immunomodulatory molecules, haematological parameters, inflammatory cells and costimulatory molecules. Conclusions. The analysed data indicate that markers associated with inflammation, oxidative stress and hormones, and cancer-related markers could be useful in assessing the severity of psoriasis. Nevertheless, additional research is required to ascertain the practical importance of these biomarkers in clinical settings. Full article
(This article belongs to the Special Issue Chronic Inflammatory Skin Disease: Where We Are and Where We Are Going)
►▼ Show Figures

Figure 1

10 pages, 858 KiB  
Review
Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature
by Fabrizio Martora, Massimiliano Scalvenzi, Angelo Ruggiero, Luca Potestio, Teresa Battista and Matteo Megna
Medicina 2023, 59(4), 801; https://doi.org/10.3390/medicina59040801 - 20 Apr 2023
Cited by 16 | Viewed by 3721
Abstract
Background: Hidradenitis suppurativa (HS), also known as acne inversa or Verneuil’s disease, is a chronic, inflammatory, recurrent, and debilitating skin disease of the hair follicles characterized by inflammatory, painful, deep-rooted lesions in the areas of the body characterized by the presence of [...] Read more.
Background: Hidradenitis suppurativa (HS), also known as acne inversa or Verneuil’s disease, is a chronic, inflammatory, recurrent, and debilitating skin disease of the hair follicles characterized by inflammatory, painful, deep-rooted lesions in the areas of the body characterized by the presence of the apocrine glands. Unfortunately, huge unmet needs still remain for its treatment. Objective: The purpose of our review was collecting all cases, case series, trials, and ongoing studies available in the literature on the use of this class of drugs for HS. Materials and Methods: The investigated manuscripts included trials, reviews, letters to the editor, real-life studies, case series, and reports. Manuscripts were identified, screened, and extracted for the relevant data following the PRISMA (preferred reporting items for systematic reviews and meta-analyses) guidelines. Results: We selected 56 articles of which 25 met the selection criteria for our review. Among the JAK inhibitors to date, there is only one published clinical trial in the literature (Janus kinase 1 inhibitor INCB054707), a real-life study with 15 patients up to week 24 in which upadacitinib was used and a case series where tofacitinib was successfully used. Conversely, there are several ongoing clinical trials. Conclusions: Results to date in the literature show promising levels of efficacy and the safety of JAK inhibitors in HS. Several clinical trials are underway from which it will be very important to compare the available data. There are still too few studies conducted with a low sample size, so it remains critical to investigate this issue further in the future with a real-life study involving a large sample of patients in order to provide safe and viable therapeutic alternatives for HS. Full article
(This article belongs to the Special Issue Chronic Inflammatory Skin Disease: Where We Are and Where We Are Going)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-6
Back to TopTop